Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer

Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer

Abstract This clinical trial combined fulvestrant with the anti-androgen enzalutamide in women with metastatic ER+/HER2− breast cancer (BC). Eligible patients were women with ECOG 0–2, ER+/HER2− measurable or evaluable metastatic BC. Prior fulvestrant was allowed. Fulvestrant was administered at 500...

Full description

Bibliographic Details
Main Authors: Anthony D. Elias, Nicole S. Spoelstra, Alyse W. Staley, Sharon Sams, Lyndsey S. Crump, Gregory A. Vidal, Virginia F. Borges, Peter Kabos, Jennifer R. Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Tessa McSpadden, Gloria Crawford, Angelo D’Alessandro, Kathryn L. Zolman, Adrie van Bokhoven, Yonghua Zhuang, Rosa I. Gallagher, Julia D. Wulfkuhle, Emanuel F. Petricoin III, Dexiang Gao, Jennifer K. Richer
Format: Article
Language:English
Published: Nature Portfolio 2023-05-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-023-00544-z

Internet

https://doi.org/10.1038/s41523-023-00544-z

Similar Items